FDA Alert: Plavix May Be Less Effective in Some Patients with Genetic Variation
What some clinicians have known about for some time is now official: the U.S. Food and Drug Administration today added a boxed warning to the drug Plavix (clopidogrel) stating that, in some patients with a genetic variation of the cytochrome CYP2C19, Plavix may not be metabolized properly and therefore may not be effective for the indicated therapy. (Source: News from Angioplasty.Org)...
POSTED 03/12/2010 at 03:45 PM --
|
Volcano Expands Access to FFR with Ability to Integrate with the Majority of Hemodynamic Monitoring Systems
The value of Fractional Flow Reserve in guiding PCI (percutaneous coronary interventions) has been shown in the FAME studies, as well as others. Yet the number of labs using FFR shows that it is an underused modality. Integrating FFR into standing hemodynamic monitoring systems simplifies the use of this valuable tool. Today Volcano announced that it is offering FFR technology integrated with the existing systems manufactured by GE, Siemens, McKesson, and Mennen. (Source: News from Angioplasty.Org)...
POSTED 03/12/2010 at 10:50 AM --
|
Volcano Announces Activities at the ACC 2010
The company announced its activities today at Annual Scientific Sessions of the American College of Cardiology (ACC) Conference taking place in Atlanta from March 14th to March 16th. Presentations and new product launches will continue Volcano's mission to demonstrate the limitations of angiography and the value of IVUS, FFR and OCT. (Source: News from Angioplasty.Org)...
POSTED 03/12/2010 at 10:45 AM --
|
[Transient subclavian artery spasm observed during percutaneous coronary intervention for acute myocardial infarction.]
Authors: Karakurt O, Kılıç H, Akdemir R
A 68-year-old man with a history of two coronary artery bypass operations was admitted with acute inferior myocardial infarction (AMI) and cardiogenic shock. The electrocardiogram showed ST-segment elevation in leads D2, D3, and aVF. Coronary angiography demonstrated a 75% thrombotic stenosis in the right coronary artery (RCA), 90-99% stenosis in the intermediate coronary artery, and plaques in the circumflex artery. While assessing the patency of bypass grafts, a 99% stenosis was noted in the distal subclavian artery. The culprit artery was deemed to be the RCA, and after direct stenting, TIMI III flow was achieved. Ten days later, stent implantation was performed for the intermediate coronary artery, at which time distal subcla......
POSTED 03/12/2010 at 05:50 AM --
|
Clinical Experience with a Novel Intracoronary Perfusion Catheter to Treat No-Reflow Phenomenon in Acute Coronary Syndromes
Conclusion:The infusion of intracoronary drugs using the novel perfusion CW RX catheter seems to be safe and could help to improve myocardial perfusion in a selected group of patients presenting with ACS who developed no-reflow during PCI. (J Interven Cardiol 2010;**:1[ndash]5) (Source: Journal of Interventional Cardiology)...
POSTED 03/11/2010 at 06:00 PM --
|
Plasma Calprotectin Predicts Mortality in Patients with ST Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention
Conclusion:Plasma calprotectin levels, determined at admission in STEMI patients successfully treated with pPCI, predict mortality over a period of 12 months, indicating that plasma calprotectin may be a new important prognostic biomarker in acute ischemic heart disease. (J Interven Cardiol 2010;**:1[ndash]7) (Source: Journal of Interventional Cardiology)...
POSTED 03/11/2010 at 06:00 PM --
|
The Use of Coronary Revascularisation Procedures in Urban Australian Aboriginals and a Matched General Population: Coronary Procedures in Aboriginals
Conclusions: Coronary revascularisation procedures for IHD were used with equal frequency in Aboriginal people and matched non-Aboriginals. Aboriginal people were more likely to have CABG than PCI. Revascularisation rate and type in ACS admissions were the same. (Source: Heart, Lung & Circulation)...
POSTED 03/11/2010 at 07:57 AM --
|
The Value of Dual-source 64-Slice CT Coronary Angiography in the Assessment of Patients Presenting to an Acute Chest Pain Service
Conclusions: The CTCA findings were significantly correlated with those of selective angiography and with troponin status and increased the ascertainment of coronary artery disease in a cohort of patients at low risk for clinically significant ischaemic heart disease. (Source: Heart, Lung & Circulation)...
POSTED 03/11/2010 at 07:57 AM --
|
Long-term effects of intracoronary bone marrow cell transfer on diastolic function in patients after acute myocardial infarction: 5-year results from the randomized-controlled BOOST trial--an echocardiographic study
Conclusion
Intracoronary autologous BMC transfer provides an overall treatment effect on echocardiographic parameters of diastolic function in patients after AMI. However, this effect is basically related to an early improvement of parameters of diastolic function without a sustained effect on long-term follow-up. (Source: European Journal of Echocardiography)...
POSTED 03/11/2010 at 03:46 AM --
|
Revascularization for coronary artery disease in diabetes mellitus: Angioplasty, stents and coronary artery bypass grafting
Abstract Patients with diabetes mellitus (DM) are prone to a diffuse and rapidly progressive form of atherosclerosis, which increases
their likelihood of requiring revascularization. However, the unique pathophysiology of atherosclerosis in patients with DM
modifies the response to arterial injury, with profound clinical consequences for patients undergoing percutaneous coronary
intervention (PCI). Multiple studies have shown that DM is a strong risk factor for restenosis following successful balloon
angioplasty or coronary stenting, with greater need for repeat revascularization and inferior clinical outcomes. Early data
suggest that drug eluting stents reduce restenosis rates and the need for repeat revascularization irrespective of the diabetic
state and with no signifi......
POSTED 03/11/2010 at 02:06 AM --
|
Ischemix Initiates Phase 2a Trial Of CMX-2043 For The Prevention Of Ischemia-Reperfusion Injury
Ischemix announced the initiation of patient accrual in a multi-center Phase 2a clinical trial of CMX-2043 for the prevention of peri-operative ischemia-reperfusion injury in patients undergoing elective percutaneous coronary intervention (PCI) procedures. CMX-2043 is a cardio-protective drug that combines Akt pathway-mediated cell survival effects and anti-oxidant activity in a single small molecule... (Source: Health News from Medical News Today)...
POSTED 03/11/2010 at 02:00 AM --
|
Ischemix Initiates Phase 2a Trial Of CMX-2043 For The Prevention Of Ischemia-Reperfusion Injury
Ischemix announced the initiation of patient accrual in a multi-center Phase 2a clinical trial of CMX-2043 for the prevention of peri-operative ischemia-reperfusion injury in patients undergoing elective percutaneous coronary intervention (PCI) procedures... (Source: Cardiovascular / Cardiology News From Medical News Today)...
POSTED 03/11/2010 at 02:00 AM --
|
Gender-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb–IIIa inhibitors: insights from the EGYPT cooperation
This study shows that in patients with STEMI treated by primary angioplasty, female gender is associated with higher
mortality rate in comparison with men, and this is mainly due to their higher clinical and angiographic risk profiles. In
fact, female sex did not emerge as an independent predictor of mortality.
Content Type Journal ArticleDOI 10.1007/s11239-010-0451-yAuthors
Giuseppe De Luca, Eastern Piedmont University Division of Cardiology, Maggiore della Carità Hospital Novara ItalyC. Michael Gibson, Harvard Medical School Beth Israel Deaconess Medical Center Boston USAMariann Gyöngyösi, Medical University of Vienna Department of Cardiology Vienna AustriaUwe Zeymer, Herzzentrum Ludwigshafen Division of Cardiology Ludwigshafen GermanyDariusz Dudek, Jagiellonian University II......
POSTED 03/10/2010 at 09:34 AM --
|
Benefit of PCI-center directed AMI care depends on referral region
The benefit of regionalizing care of acute myocardial infarction patients to hospitals capable of performing percutaneous coronary intervention depends on the hospital referral region. (Source: MedWire News - Cardiology)...
POSTED 03/10/2010 at 08:26 AM --
|
Resting Heart Rate and Metabolic Syndrome in Patients With Diabetes and Coronary Artery Disease in Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial
Prev Cardiol. ****;**:**[ndash]**. The relation between the metabolic syndrome (MetS) and resting heart rate (rHR) in patients with diabetes and coronary artery disease is unknown. The authors examined the cross-sectional association at baseline between components of the MetS and rHR and between rHR and left ventricular ejection fraction in the population from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) randomized clinical trial. The mean rHR in the MetS group was significantly higher than in those without (68.4±12.3 vs 65.6±11.8 beats per min, P=.0017). The rHR was higher (P (Source: Preventive Cardiology)...
POSTED 03/09/2010 at 06:00 PM --
|
A Novel Approach to Transplanting Bone Marrow Stem Cells to Repair Human Myocardial Infarction: Delivery via a Noninfarct-relative Artery
The objective of the present study was to evaluate the safety and feasibility of autologous bone marrow mesenchymal stem cell transplantation via such an approach in patients with acute myocardial infarction (AMI). Sixteen patients with anterior AMI who had successfully undergone percutaneous coronary intervention (PCI) were enrolled in this pilot, randomized study. Three weeks after PCI, cultured bone marrow mesenchymal stem cells were injected into the myocardium via either the infarct-relative artery (left anterior descending branch artery, LAD) or a noninfarct-relative artery (right coronary artery, RCA). The safety and feasibility of the cell infusion were evaluated during the procedure and during 6 months of follow-up. In addition, 2D echocardiography, technetium-99m methoxyisobutyli......
POSTED 03/09/2010 at 06:00 PM --
|
Left Ventricular Remodeling and Heart Failure After Myocardial Infarction in Elderly Patients
We read with interest the recent report by Carraba et al on the effect of age on left ventricular remodeling (LVR) and heart failure (HF) in patients treated by primary angioplasty for myocardial infarction (MI). The study demonstrated that despite very few differences in LVR, elderly patients had a much greater risk of HF at long-term follow-up. As noted by the authors, their study was, however, performed in a selected population as patients receiving lytic treatment or patients with clinical signs of HF during the first week after MI were excluded. (Source: The American Journal of Cardiology)...
POSTED 03/09/2010 at 07:57 AM --
|
Differences in Patient Survival After Acute Myocardial Infarction by Hospital Capability of Performing Percutaneous Coronary Intervention: Implications for Regionalization [Original Investigation]
Conclusions The magnitude of benefit from comprehensively regionalizing AMI care to PCI hospitals appears to vary greatly across HRRs. These findings support a tailored regionalization policy that targets areas with the greatest outcome differences between PCI and local non-PCI hospitals. (Source: Archives of Internal Medicine)...
POSTED 03/08/2010 at 02:50 PM --
|
Avoiding Intelligence Failures in the Cardiac Catheterization Laboratory: Strategies for the Safe and Rational Use of Dalteparin or Enoxaparin During Percutaneous Coronary Intervention
LMWH approaches in the cath lab can be readily monitored with the point-of-care activated clotting time (ACT) assay. This review explains how and why. The Journal of Invasive Cardiology (Source: Medscape Today Headlines)...
POSTED 03/08/2010 at 06:04 AM --
|
Single-session endovascular treatment for symptomatic lower extremity deep vein thrombosis: a feasibility study.
Conclusion: Single-session endovascular treatment is a feasible technique that provides acceptable technical and clinical success with excellent safety for treating symptomatic lower extremity DVT.
PMID: 20201636 [PubMed - in process] (Source: Acta Radiologica)...
POSTED 03/07/2010 at 08:28 AM --
|
